Aducanumab, sold under the brand name Aduhelm, is used t...
wikipedia - 08 Jun 2021Aducanumab, sold under the brand name Aduhelm, is used to treat Alzheimer's disease (AD). It is an amyloid beta-directed antibody.
Aducanumab
Aducanumab, sold under the brand name Aduhelm, is used to treat Alzheimer's disease (AD). It is an amyloid beta-directed antibody.
Aducanumab delivery via focused ultrasound-induced transient blood–brain barrier opening in vivo
Nature - 22 May 2025Aducanumab delivery via focused ultrasound-induced transient blood–brain barrier opening in vivo ...
A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system
Frontiers - 18 Feb 2025A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system ...
The Aducanumab Controversy: Accelerated FDA Approval Leads to Agency Distrust
Neurology Advisor - 19 Jul 2024The Aducanumab Controversy: Accelerated FDA Approval Leads to Agency Distrust ...
HHS Inspector General Raises Concerns Over FDA's Accelerated Approvals
MedPage Today - 16 Jan 2025HHS Inspector General Raises Concerns Over FDA's Accelerated Approvals ...
Biogen blames "misinformation" for fallout over Aduhelm approval
FirstWord Pharma - 20 Mar 2025Biogen blames "misinformation" for fallout over Aduhelm approval ...
Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system
Frontiers - 29 May 2025Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system ...
Refractory Status Epilepticus in a Patient With Aducanumab-Induced Amyloid-Related Imaging Abnormalities
Neurology® Journals - 09 Aug 2024Refractory Status Epilepticus in a Patient With Aducanumab-Induced Amyloid-Related Imaging Abnormalities ...
Ethical Considerations for FDA Accelerated Approval
The Regulatory Review - 07 Dec 2024Ethical Considerations for FDA Accelerated Approval ...
Aducanumab for Alzheimer’s disease?
The BMJ - 05 Jul 2021Aducanumab for Alzheimer’s disease? ...
Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease
The New England Journal of Medicine - 03 Jan 2024Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease ...
Aducanumab debate: Expert views on Biogen's Alzheimer drug
MedicalNewsToday - 11 Jan 2023Aducanumab debate: Expert views on Biogen's Alzheimer drug ...
Biogen Abandons Aducanumab, Pivots Focus to Lecanemab for Alzheimer Disease
AJMC - 31 Jan 2024Biogen Abandons Aducanumab, Pivots Focus to Lecanemab for Alzheimer Disease ...
Biogen to Realign Resources for Alzheimer's Disease Franchise
Biogen - 31 Jan 2024Biogen to Realign Resources for Alzheimer's Disease Franchise ...
2021: Anti-amyloid antibodies take a bumpy road to the clinic
Nature - 26 Sep 20242021: Anti-amyloid antibodies take a bumpy road to the clinic ...
Biogen terminates phase 4 efficacy study of aducanumab
UCI MIND - 31 Jan 2024Biogen terminates phase 4 efficacy study of aducanumab ...
Ultra-early detection and treatment of Alzheimer's disease through sonoporation-mediated intracellular delivery of ICG-labeled aducanumab
ScienceDirect.com - 14 Jul 2024Ultra-early detection and treatment of Alzheimer's disease through sonoporation-mediated intracellular delivery of ICG-labeled aducanumab ...
A Real-World Pharmacovigilance Study of Adverse Drug Reactions Associated with Lecanemab and Aducanumab Based on WHO-VigiAccess and FAERS Databases
Frontiers - 03 Mar 2025A Real-World Pharmacovigilance Study of Adverse Drug Reactions Associated with Lecanemab and Aducanumab Based on WHO-VigiAccess and FAERS Databases ...
Heed the Warning Signs to Avoid Serious ARIA
Neurology® Journals - 09 Aug 2024Heed the Warning Signs to Avoid Serious ARIA ...
Alzheimer's Data Withdrawn
MedPage Today - 11 Nov 2024Alzheimer's Data Withdrawn ...